Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

76.85 -0.66 (-0.85%)
Streaming Delayed Price Updated: 1:33 PM EDT, Oct 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Astrazeneca Plc ADR

< Previous 1 2 3 4 5 6 7 8 9
...
48 49 Next >
Sanofi Reports Strong Earnings, Joins Kirby, Sonic Automotive, Union Pacific And Other Big Stocks Moving Higher On Thursday
Via Benzinga
AstraZeneca Posts Bumper Earnings On Strong Sales From Cancer Drugs, Sticks To Annual Guidance
AstraZeneca reports Q1 sales of $12.68 billion, up 17% Y/Y. Despite missing adjusted EPADS, oncology sees a 26% surge, driven by Tagrisso and Imfinzi. Cardiovascular sales up 20%. R&D up 18%. Fiscal... 
Via Benzinga
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
The radiopharmaceuticals space could be worth up to $25 billion, according to one estimate. 
Via Investor's Business Daily
AZN Stock Earnings: AstraZeneca Misses EPS, Beats Revenue for Q1 2024
AZN stock results show that AstraZeneca missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Should Quality-Oriented Investors Explore ASTRAZENECA PLC-SPONS ADR (NASDAQ:AZN)?
Why Quality-Oriented Investors Should Consider NASDAQ:AZN. 
Via Chartmill
Looking At AstraZeneca's Recent Unusual Options Activity
Via Benzinga
A Closer Look at AstraZeneca's Options Market Dynamics
Via Benzinga
AstraZeneca, Sanofi Jump On First-Quarter Earnings; Bristol Myers Lags
AstraZeneca soundly topped analyst views while Sanofi narrowed its losses. Both stocks surged in early trade. 
Via Investor's Business Daily
US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst
The back-and-forth motion in the market continues, with the index futures pointing to a lower opening on Thursday. Meta Platforms, Inc.’s (NASDAQ:META) 
Via Benzinga
3 Underappreciated Pharmaceutical Stocks to Buy Before They Surge
These are the undervalued pharmaceutical stocks to buy as they have a deep clinical pipeline which will driven earnings and cash flow growth. 
Via InvestorPlace
European Stock: AstraZeneca
AstraZeneca PLC is a science-led biopharmaceutical company. The company focuses on the discovery, development, and commercialization of prescription medicines in oncology, rare diseases, and... 
Via Talk Markets
Brexit Impact On Drugs - Rising Shortages in UK Highlight Brexit Challenges
Discover the impact of Brexit on UK drug shortages. Insights from a recent Nuffield Trust study reveal a doubling in shortages since 2020. Learn about challenges in medicine supplies, regulatory... 
Via Benzinga
Topics Brexit
Exposures Brexit
3 Blue-Chip Stocks to Buy as High Inflation Persists
These are the undervalued blue-chip stocks for inflation protection, with the Fed likely to delay the first interest rate cut. 
Via InvestorPlace
Topics Economy
Exposures Interest Rates
Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick
Amgen's Tezspire shows promising COPD trial results and potential market expansion beyond asthma. Comparison with Dupixent reveals significant benefits for eosinophil counts ≥150 cells/μL and ≥300... 
Via Benzinga
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
Corporate profit growth rose in Q3 2023 and is expected to continue in Q1. 
Via Benzinga
AstraZeneca's Imfinzi/Chemo Combo Doubles Overall Survival In Biliary Tract Cancer Patients At 3 Years, Data Shows
AstraZeneca's updated data from TOPAZ-1 Phase 3 trial of Imfinzi (durvalumab) in advanced biliary tract cancer patients. Unveiling long-term survival benefits and significant overall survival... 
Via Benzinga
3 Pharma Stocks That Are Money-Printing Machines in 2024
The economy, and pharma industry, are projected to grow massively. You should invest in these top three pharma stocks. 
Via InvestorPlace
Topics Economy
Exposures Economy
4 Exceptional Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
Amazing deals can still be found by opportunistic investors, even with the Nasdaq Composite reaching new heights. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Novo Nordisk/Eli Lilly's Weight Loss Drugs Does Not Cause Suicidal Behaviors - After FDA, European Medicines Agency Says
The European Medicines Agency's Pharmacovigilance Risk Assessment Committee found no conclusive evidence linking GLP-1 receptor agonists to suicidal or self-injurious thoughts. Following thorough... 
Via Benzinga
Exposures Product Safety
AstraZeneca Hikes Annual Dividend By 7% Just Before Vote On Its CEO's Pay Package Boost
AstraZeneca boosts its 2024 dividend to $3.10/share, reflecting confidence in performance. Shareholder concerns addressed as CEO compensation proposal approaches vote. Recent acquisitions and FDA... 
Via Benzinga
Exposures Product Safety
AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor
FDA approves Daiichi Sankyo's and AstraZeneca's Enhertu for unresectable or metastatic HER2+ solid tumors. Accelerated approval based on ORR and DOR. Boxed warnings for ILD/pneumonitis and embryo-fetal... 
Via Benzinga
Exposures Product Safety
US Manufacturing Hits 18-Month High, China's Growth Could Trigger Deflation And More: Economics Weekly Roundup
This week's top stories highlight significant developments, including the U.S. manufacturing sector reaching an 18-month high, potential deflation from China's manufacturing growth, a robust U.S. labor... 
Via Benzinga
Topics Economy
Exposures Interest Rates
New Hope for Aggressive Lung Cancer: AstraZeneca's Imfinzi Shows Promising Results in Phase 3 Trial
High-level results of AstraZeneca's ADRIATIC Phase 3 trial on Imfinzi monotherapy & Imfinzi plus Imjudo for limited-stage small cell lung cancer. Statistically significant OS & PFS improvement shown... 
Via Benzinga
AstraZeneca CEO Highlights Decade-Long Sales Goal Of $45B Along With Investor Doubts As It Lags In Weight Loss Race
AstraZeneca's CEO Pascal Soriot celebrates hitting a $45 billion sales target set a decade ago despite initial skepticism. Investor confidence remains a challenge amid stagnant shares and concerns over... 
Via Benzinga
7 Blue-Chip Stocks That Will Outperform the Dow in the 5 Five Years
These are the blue-chip stocks to outperform Dow in the next five years and represents companies with growth and cash flow visibility. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
Bull Market Buys: 3 Dividend Stocks to Own for the Long Run
Invest in stability, dividends, and growth with these three accomplished real estate operators. 
Via The Motley Fool
What's Going On European Pharma Giant AstraZeneca Stock On Wednesday?
Japan approves AstraZeneca & Sanofi's Beyfortus for respiratory syncytial virus in neonates, infants, & children. Also, Truqap receives approval for unresectable or recurrent breast cancer. AstraZeneca... 
Via Benzinga
EXCLUSIVE: 2024 Witnesses Increase In Biotech Initial Public Offerings
Dr. Laura Chico, Senior VP at Wedbush, is optimistic about 2024 biotech IPO market and M&A trends. Election year may affect performance. 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
After Failed Prostate Cancer Study Merck's Keytruda Combination Therapy Flunks In Late-Stage Lung Cancer Study
Merck's latest findings from the KEYLYNK-006 trial on Keytruda and Lynparza combination therapy for metastatic non-small cell lung cancer reveal outcomes on survival and progression. 
Via Benzinga
Senator Bernie Sanders Applauds GSK's Move To Cap Inhaler Costs At $35 Per Month
GSK caps asthma and COPD medicine costs at $35/month, effective Jan 1, 2025. Includes Advair, Breo, Ventolin. Follows AstraZeneca's suit for their respiratory medicines. Sanders applauds move amid... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
48 49 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.